AstraZeneca Pharma India Limited, a science-led biopharmaceutical company, achieved a 31% increase in revenue in Q1 FY25 compared to the same period last year to reach Rs. 387.5 crore.  

Profit before exceptional item and tax is Rs. 42.4 crore (11% of the total income) reflecting the company’s efforts on driving profitable growth. Loss after exceptional item and tax is Rs. 11.79 crore (-3% of total income) due to booking of provisions associated with exit of factory site announced in this quarter.

Dr. Sanjeev Panchal, Country President and Managing Director, AstraZeneca India said, "We are pleased to report a strong financial performance this quarter. It reflects our continuous endeavour of harnessing science and commitment to bringing innovative medicines faster to India. We are focused on our ambition to ensure our therapies reach the patients who need them the most and are constantly working to tailor sustainable programs focused on early diagnosis and improved access to meet local needs by collaborating with healthcare systems, payers, policymakers, and non-government organizations."

Bhavana Agrawal, Chief Finance Officer said, "It’s a strong start of the year with 31% revenue growth and double-digit profit margin (before exceptional item and tax). The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years. We are continuously pushing the boundaries of science and are well positioned for consistent value creation for our customers and shareholders.”

AstraZeneca India continues to advance its mission of transforming the future of healthcare by unlocking the power of science for the benefit of people, society, and the planet. The company's commitment to innovation is reflected in its strong pipeline progress, reinforcing its position as a key player in the healthcare industry.

The company has also partnered with Vaayu Chest & Sleep Center to elevate the standard of respiratory care for severe asthma patients by setting up a Center of Excellence (CoE) in Bengaluru.